In locally advanced head and neck cancer, outcomes with anti‑PD‑L1 avelumab plus standard‑of‑care chemoradiotherapy vary by tumor ecosystem, with increased myeloid/neutrophil activities and intratumoral bacteria linked to worse outcomes versus placebo/chemoradiotherapy

In locally advanced head and neck cancer, outcomes with anti‑PD‑L1 avelumab plus standard‑of‑care chemoradiotherapy vary by tumor ecosystem, with increased myeloid/neutrophil activities and intratumoral bacteria linked to worse outcomes versus placebo/chemoradiotherapy - Vera Health 뉴스